Rosa was 28, a graduate student in Philadelphia who had been hospitalised for a manic episode with psychotic features and started on haloperidol with rapid dose escalation over four days. By the fifth day she had a temperature of 40.1°C, lead-pipe rigidity in all four extremities, blood pressure swinging between 180/110 and 90/60, and a creatine kinase of 4,800. The on-call psychiatry resident, who had only ever read about neuroleptic malignant syndrome in a board-review book, recognised the tetrad on morning rounds and pushed for an immediate ICU transfer. The intensivist initially thought it was sepsis, but the medication reconciliation, the rigidity, and the CK trend made the diagnosis unmistakable. Haloperidol stopped that hour. Dantrolene started within two. Bromocriptine added that evening. Rosa spent eleven days in the unit, returned to the psychiatry floor for another two weeks, and was discharged on quetiapine with a chart flag the size of a billboard. She finished her dissertation eighteen months later. The resident still keeps the printed lab trend in a folder she shows to interns.
The pathophysiology in one paragraph
The proximate mechanism of neuroleptic malignant syndrome is acute dopamine D2 receptor blockade in critical brain regions: the basal ganglia (rigidity), the hypothalamus (hyperthermia), the brainstem (autonomic instability), and the cortex (altered mental status). Antipsychotics with the highest D2 affinity (haloperidol, fluphenazine) carry the highest risk. Atypicals are not exempt, particularly at high doses or in combination. Withdrawal of dopaminergic agents in Parkinson’s disease can produce an indistinguishable syndrome (sometimes called parkinsonism-hyperpyrexia syndrome).
The classic tetrad
Most cases evolve over 24 to 72 hours, occasionally faster. The four core features that should trigger immediate diagnostic consideration:
- Hyperthermia: temperatures of 38.5–42°C; resistant to acetaminophen because the cause is muscular rather than central thermoregulatory shift
- Rigidity: lead-pipe (uniform throughout range of motion), often with cogwheeling; severe cases involve respiratory muscles and contribute to ventilatory failure
- Autonomic instability: labile blood pressure, tachycardia, diaphoresis, urinary incontinence, sialorrhea
- Altered mental status: ranges from confusion and agitation to mutism, stupor, and coma; patients with prior catatonia are at particular risk
The Levenson criteria require all four cardinal features. The Caroff and Mann criteria allow diagnosis with a less complete picture if the clinical context supports it. In practice, hyperthermia plus rigidity plus an antipsychotic exposure should drive workup and treatment regardless of which formal criteria are applied.
Risk factors that make NMS more likely
NMS is rare overall (incidence around 0.01–0.02 percent of antipsychotic exposures with modern prescribing), but identifiable risk factors raise the probability substantially.
- High-potency typical antipsychotics, particularly haloperidol and fluphenazine
- Rapid dose titration over hours or days
- Parenteral administration (IM long-acting injectables, repeated IM haloperidol)
- Dehydration, especially in agitated patients refusing fluids
- Physical restraint with continued struggling
- Pre-existing catatonia, which shares pathophysiology and can convert
- Iron deficiency
- Prior episode of NMS (recurrence risk roughly 30 percent)
- Multiple antipsychotics or addition of lithium to an antipsychotic
- Acute medical illness with elevated baseline temperature
The settings most likely to produce NMS are emergency departments, where acutely agitated patients receive repeated IM haloperidol while being restrained, and inpatient psychiatric units doing rapid titration on a young patient with mania. The intersection of agitation, dehydration, restraint, and high-potency D2 blockade is the highest-risk scenario in modern practice.
The labs and what they tell you
Confirmation is clinical, but laboratory findings strongly support the diagnosis and guide management.
- Creatine kinase elevated above 1,000, often into the 10,000+ range; values track severity and guide rhabdomyolysis management
- Leukocytosis 10–40,000 without left shift
- Elevated transaminases
- Metabolic acidosis
- Renal function decline from rhabdomyolysis-related myoglobinuria
- Iron studies: low serum iron is found in roughly two-thirds of cases
- Coagulation panel for emerging DIC in severe cases
A normal CK does not rule out early NMS. The rise often lags the clinical picture by hours. Serial measurements every six to twelve hours are more informative than any single value.
Management: ICU-level supportive care plus targeted therapy
The first step is to stop all dopamine antagonists. The second is to escalate the level of care to an ICU because rapid deterioration is common and respiratory failure from rigidity-related hypoventilation is a leading cause of death. Beyond that:
- Aggressive IV crystalloid resuscitation, with goal urine output of 200–300 mL/hour to protect kidneys from rhabdomyolysis
- External cooling (cooling blankets, ice packs to groin and axillae) for temperatures above 39.5°C
- Benzodiazepines (lorazepam IV at 1–2 mg every 4–6 hours, sometimes higher) to reduce agitation and muscular activity
- Dantrolene 1–2.5 mg/kg IV every 6 hours, titrated to clinical response, for severe rigidity and hyperthermia
- Bromocriptine 2.5–5 mg every 8 hours via NG tube, working as a dopamine agonist to counter the underlying blockade
- Amantadine as an alternative dopaminergic agent
- ECT for refractory cases or when distinguishing NMS from malignant catatonia is clinically impossible
- Intubation and paralysis with non-depolarising agents if respiratory failure or extreme hyperthermia persist
Succinylcholine is generally avoided for intubation in this setting because of the risk of hyperkalaemia from rhabdomyolysis. Vecuronium or rocuronium are preferred. Treatment continues until clinical resolution, typically 7–14 days, with slow taper of dantrolene and bromocriptine over an additional week or two to prevent recrudescence.
Distinguishing NMS from serotonin syndrome and malignant catatonia
The differential matters because management diverges. Compared with serotonin syndrome, NMS:
- Onsets in days, not hours
- Has lead-pipe rigidity rather than hyperreflexia and clonus
- Has hypoactive bowel sounds rather than hyperactive
- Has normal or sluggish pupils rather than mydriasis
- Resolves over 1–2 weeks rather than 24–72 hours
Malignant catatonia and NMS are increasingly considered overlapping syndromes; some authors describe NMS as a drug-induced subtype of malignant catatonia. The treatment overlap is meaningful: both respond to benzodiazepines and to ECT, and both require stopping antipsychotics. Rare cases of malignant hyperthermia from anaesthetic exposure produce similar physiology; capnography findings and recent anaesthetic history clarify.
Restarting antipsychotics safely
The recurrence risk after a single NMS episode is roughly 30 percent if the same agent is restarted, and substantially lower with careful agent selection and slow titration. Best practice involves:
- Waiting at least two weeks after full clinical resolution and CK normalisation
- Switching to a low-potency atypical (quetiapine, olanzapine, clozapine) rather than restarting the offending agent
- Starting at the lowest possible dose with weekly increments rather than daily
- Avoiding parenteral routes where possible
- Maintaining hydration and avoiding restraint where possible
- Documenting the NMS history prominently in the chart and on a wallet card
Clozapine has the lowest reported NMS rate of any antipsychotic and is sometimes used after recovery in patients who require ongoing treatment. The trade-off involves the agranulocytosis monitoring and metabolic burden, and the decision is best made in specialist pharmacology consultation.
Mortality and long-term outcomes
Mortality from NMS in the modern era is roughly 5–10 percent, down from 20–30 percent in the era before recognition and ICU support. Death usually results from respiratory failure, cardiovascular collapse, renal failure from rhabdomyolysis, or pulmonary embolism in the prolonged immobility of severe cases. Sequelae after recovery are uncommon but include persistent parkinsonism in roughly 5 percent of cases. The underlying psychiatric condition still needs treatment, and the post-recovery psychiatric trajectory often dictates long-term outcome more than the NMS itself.
Special populations: pediatrics, pregnancy, and Parkinson’s
NMS in children and adolescents is rare but increasingly seen as second-generation antipsychotics are prescribed off-label for autism-related agitation, severe ADHD, and Tourette syndrome. The clinical picture in children can be more subtle, with rigidity less prominent and altered mental status easier to miss in non-verbal patients. Any child on an antipsychotic who develops fever, sweating, and unexplained somnolence deserves a CK and a careful neurological exam.
In pregnancy NMS poses risks to both mother and fetus, including miscarriage and preterm labour from the underlying hyperthermia. The treatment principles are unchanged, but dantrolene crosses the placenta and bromocriptine is generally avoided in lactation. Multidisciplinary care between psychiatry, obstetrics, and maternal-fetal medicine is essential. In Parkinson’s disease, abrupt withdrawal of levodopa or dopamine agonists can produce a syndrome clinically indistinguishable from NMS; treatment is to restart the dopaminergic agent rather than to add antipsychotics.
Patients on long-acting injectable antipsychotics who develop NMS face a particularly difficult course because the offending drug cannot simply be stopped. Depot fluphenazine, haloperidol decanoate, and the longer-acting aripiprazole formulations may continue to release drug for weeks. Aggressive supportive care, dantrolene, bromocriptine, and ECT are sometimes required for the entire half-life of the depot, and the decision to ever restart any antipsychotic in such a patient is one of the harder judgment calls in psychiatry.
Antiemetics with D2 blockade deserve their own warning. Metoclopramide and prochlorperazine, prescribed routinely on medical and surgical wards for nausea, are pharmacologically antipsychotics and have caused fully developed NMS in vulnerable patients. The risk is highest when these agents are combined with other dopamine antagonists, given to dehydrated patients, or used long enough to accumulate. Clinicians outside psychiatry frequently underestimate this risk because the drugs are perceived as gastrointestinal medications. Charting any episode of antiemetic-related extrapyramidal symptoms or hyperthermia in the same way as an antipsychotic-related episode helps the next prescriber avoid repeating the exposure.
Frequently asked questions
How long does it take for NMS to resolve?
Typically 7–14 days from drug discontinuation to full clinical resolution, longer if a long-acting injectable was the offender. CK normalisation often lags by another week.
Can atypical antipsychotics cause NMS?
Yes. Risperidone, olanzapine, quetiapine, and others have all been reported. The presentation may be milder, with less rigidity and more autonomic features, sometimes called atypical NMS.
Should the patient ever take an antipsychotic again?
If the underlying disorder requires it, yes, with the precautions outlined above. Untreated psychosis or mania can be more dangerous than the recurrence risk of NMS.
Is dantrolene the same drug used in malignant hyperthermia?
Yes. It works on the ryanodine receptor to reduce calcium release from the sarcoplasmic reticulum, which dampens muscle contraction.
Can I get NMS from one dose of haloperidol?
Rare, but reported. Most cases follow several days of exposure, but susceptibility varies and a small number of patients react after a single high dose, particularly in the context of dehydration and restraint.
The bottom line
Neuroleptic malignant syndrome is rare, dramatic, and treatable when recognised promptly. The tetrad of hyperthermia, rigidity, autonomic instability, and altered mental status in any patient on an antipsychotic should trigger immediate consideration. Stop the antipsychotic, transfer to ICU, hydrate aggressively, sedate with benzodiazepines, add dantrolene and bromocriptine for severity, and consider ECT for refractory cases. Restart antipsychotics later, slowly, with a different agent. Rosa, the graduate student in our opening, defended her dissertation in front of a committee that knew nothing of those eleven days in the ICU. She titles her email signature with the position she earned afterward, and credits her recovery to the resident who knew the tetrad.
Anyone in mental health crisis can call or text the 988 Suicide and Crisis Lifeline 24/7. For drug labelling and safety alerts, consult the U.S. Food and Drug Administration; for the underlying neurology of movement disorders that complicate or mimic NMS, the National Institute of Neurological Disorders and Stroke publishes accessible reviews.
This article is for educational purposes only and is not medical advice. Suspected neuroleptic malignant syndrome is a medical emergency requiring immediate evaluation. Call 911 or go to the nearest emergency department, and bring the patient’s complete medication list and recent dosing history.